Developer docs
API playgroundTry for free, no card

Search company profiles

Porton Advanced Solutions

Full company profile

uuid0000hhp

Namestring
Porton Advanced Solutions
Legal namestring
Porton Advanced Solutions LLC
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Porton Advanced Solutions is a privately held cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) founded in 2018 as a wholly-owned subsidiary of Porton Pharma Solutions, Ltd. (Shenzhen Stock Exchange: 300363). It is operationally headquartered in Cranbury, New Jersey (United States), with two cGMP manufacturing sites in Suzhou, China (Ascendas Park Campus and Mulberry Field Island / BioBay Campus). The company serves global pharmaceutical and biotechnology developers of advanced therapy medicinal products (ATMPs), serving 250+ customers across multiple modalities including cell therapies, gene therapies, mRNA therapeutics, oncolytic bacteria, and exosomes.

The company's core offering is an end-to-end ATMP platform spanning plasmids, viral vectors (lentivirus, AAV, oncolytic viruses, adenovirus), cell engineering (CAR-T, TCR-T, CAR-NK, TIL, MSC, HSC, iPSC-derived products), mRNA/LNP, bacterial vectors, and exosomes. Notable proprietary technology components include the LV-SMART® serum-free HEK293T suspension lentiviral platform (>5E07 TU/mL infectious titer, FDA DMF-registered MCB/WCB), the AAVantage® AI-guided AAV capsid library platform (co-developed with BioMap using a 100B-parameter multimodal LLM), an in vivo CAR-T LV capability at 1×10⁹ TU/mL with batch scales up to 1×10¹² TU, and clinical-grade MaxCyte ExPERT GTx flow electroporation (the first at a cell engineering CDMO in China). The firm supports iPSC-derived therapies at >1,000 batches/year scale and runs 215,000 sq ft of GMP space with 10 viral vector lines and 12 cell therapy suites (2 commercial). Quality systems are compliant with FDA, EU, and NMPA GMP requirements; 25 IND clearances have been supported with a stated 100% zero-deficiency submission success rate.

The business model combines several revenue streams: (1) fee-for-service CDMO contracts (quote-based, project-scoped) covering process development, GMP manufacturing, fill/finish, and analytical release for clinical and commercial programs; (2) sale of off-the-shelf FDA DMF-registered LV-SMART helper plasmids (VSV-G DMF #29485, Rev #29473, GagPol DMF #29421); (3) catalog research products (AAV packaging across 20+ serotypes at $1,399–$15,699 per unit, plasmid preparation, lentivirus, mRNA) with publicly listed pricing aimed at academic and industrial research customers; (4) pipeline licensing of internal and client CAR-T candidates (PAS-001 through PAS-011) to international innovators; and (5) managed Investigator-Initiated Trial (IIT) services bundling GMP manufacturing with regulatory, ethics/HGRAC submissions, PI selection, patient recruitment, and clinical data collection — most recently anchored by an MOU with Dark Horse Consulting Group (April 2026) targeting overseas sponsors entering China. Go-to-market is sales-led B2B with field account coverage, conference-driven demand generation (ASGCT 2024 Baltimore, 2026 Boston booth #831), gated scientific content (whitepapers, brochures, peer-reviewed publications), and channel partnerships with consulting firms (DHCG) and raw-material suppliers (T&L Biotechnology).

Short descriptiontext

Porton Advanced Solutions is a privately held cell and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes to global pharmaceutical and biotech sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCranbury, United States
HQ citystring
Cranbury
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy CDMO, gene therapy CDMO, plasmid manufacturing, viral vector production, mRNA LNP services
Industry5 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cell and Gene Therapy CDMO
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1CDMO Manufacturing Services
TypeProfessional Services
Description

Fee-for-service contract development and GMP manufacturing for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes, from process development through IND-enabling CMC, GMP production, fill/finish, and release testing. Quote-based, project-scoped engagements with milestone billing.

portonadvanced.com
2Pipeline Licensing Service
TypeLicensing Royalties
Description

Licensing-out of client/internal cell therapy pipelines (e.g., PAS-001 NKG2DL CAR-T for glioblastoma/colorectal/HCC, PAS-009/PAS-010 Mesothelin CAR-T, PAS-011 CD19 CAR-T for R/R B-ALL which is NMPA-approved) to international innovators. Generates licensing/royalty revenue.

portonadvanced.com
3Off-the-Shelf Helper Plasmid Products
TypeHardware Sales
Description

Sale of ready-to-use, FDA DMF-registered LV-SMART™ helper plasmids (VSV-G DMF #29485, Rev DMF #29473, GagPol DMF #29421) in 1mg, 5mg, and 10mg vials for lentiviral vector manufacturing.

portonadvanced.com
4Research & Preclinical Catalog Products
TypeOne Time License
Description

Catalogue sales of AAV packaging (20+ serotypes, $1,399–$15,699 per unit), plasmid DNA preparation (miniprep through industrial grade), lentivirus, and mRNA products to academic and industrial research customers with publicly listed unit pricing.

portonadvanced.com
5Investigator-Initiated Trial (IIT) End-to-End Services
TypeManaged Services
Description

Managed IIT service bundles covering GMP manufacturing, IIT application, ethics/HGRAC submissions, PI and site selection, patient recruitment, clinical data collection, and analysis — coordinated with clinical/nonclinical CRO partners as project-managed services.

portonadvanced.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details4 tiers
1AAV packaging off-the-shelf (research-grade)
ModelUnit Pricing
Notes

Advanced-Mini (200 µL, >1E13 GC/mL): $1,399.00; Advanced-Medium (500 µL): $1,899.00; Advanced-Large (1 mL): $2,999.00; Advanced-XLarge (5 mL, chrom-purified): $9,699 and up; Advanced-XXLarge (10 mL, chrom-purified): $15,699 and up. Available for 20+ serotypes.

portonadvanced.com
2Plasmid preparation services (research-grade)
ModelUnit Pricing
Notes

Miniprep 25 µg (1–2 days); Midiprep 350 µg (3–4 days); Maxiprep/Megaprep 1.2 mg (3–4 days); Gigaprep 15 mg (5–8 days); Industrial Grade 20 mg–1 g (1–2 weeks). Endotoxin-free, sterile options available. Specific price points not publicly disclosed.

portonadvanced.com
3LV-SMART™ GMP-grade off-the-shelf helper plasmids
ModelUnit Pricing
Notes

VSV-G (DMF #29485), Rev (DMF #29473), GagPol (DMF #29421) available in 1mg, 5mg, and 10mg vials. Minimum purchasing unit for GMP grade is 1 vial of 5mg; research/GMP-like available in 1mg or 5mg vials. Specific unit prices not publicly listed.

portonadvanced.com
4CDMO clinical & commercial manufacturing
ModelOther
Notes

Project-specific, quote-based pricing for GMP manufacturing, fill/finish, process development, analytical services, and pipeline licensing. Not publicly disclosed; obtained via contact form / inquiry.

portonadvanced.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1LV-SMART®
Description

Proprietary HEK293T-based lentiviral vector suspension, serum-free GMP manufacturing platform developed by Porton Advanced, with FDA DMF-registered master cell bank.

portonadvanced.com
+1 more record
Core offering1 text field

Porton Advanced Solutions provides end-to-end contract development and manufacturing (CDMO) services for advanced therapy medicinal products (ATMPs), spanning plasmid DNA, lentiviral and AAV viral vectors, mRNA/LNP, bacterial vectors, exosomes, and engineered cell therapies (CAR-T, TCR-T, CAR-NK, TIL, MSC, iPSC-derived). The company operates from US headquarters in Cranbury, NJ and two cGMP manufacturing sites in Suzhou, China, offering process development, analytical/QC testing, GMP manufacturing, fill/finish, regulatory support (NMPA/FDA/EMA), and pipeline licensing for cell and gene therapy developers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 100% submission success rate (zero-deficiency IND filings)
+6 more records
Product overview1 text field

Porton Advanced Solutions delivers an integrated platform-plus-modules ATMP CRO/CDMO architecture organized around three end-to-end service pillars: Research & Preclinical Services (vector construction, virus packaging, mRNA and LNP, gene editing, off-the-shelf products), CDMO Solutions (Cell Engineering CMC Services, Plasmid, Lentivirus, mRNA and LNP, Bacterial Vector, Exosome, iPSC-derived Cell Therapies, GMP Lentivirus Helper Plasmids, LV-SMART®-LVVs Suspension Production Platform, Adeno-Associated Virus), and Innovative Services (Integrated CMC Service for Investigator-Initiated Clinical Trials, Pipeline Licensing Service, Analytical Development and Testing). The LV-SMART®-LVVs Suspension Production Platform and AAVantage® Novel AAV Capsid Library Platform function as cross-cutting proprietary platforms that power the Lentivirus and AAV CDMO modules respectively. GMP Manufacturing (160,000 m² across two Suzhou sites) and the seven Functional Analytical Platforms (Physicochemical & Characterization, Microbiology, Molecular Studies, Biochemical, Cell Function, FACS) underpin all modules with shared QC, Process Development, and Quality Systems infrastructure. The offering is a single integrated CDMO platform with named product modules rather than a unified packaged product, supported by Pipeline Licensing of CAR-T candidates (PAS-001 to PAS-011) for in-licensing partners.

Product and service6 records
1Cell Engineering CMC Services
CategoryCore CDMO Module
Description

End-to-end CMC services for engineered cell therapies including CAR-T, TCR-T, CAR-NK, MSC, TIL, NK, and iPSC-derived cell products, with full process development, cGMP manufacturing, testing, and regulatory assistance for global cell therapy developers.

2Plasmid CDMO
CategoryCore CDMO Module
Description

Plasmid DNA manufacturing service for naked plasmid DNA, mRNA, AAV, lentiviral, and episomal iPSC reprogramming vectors, including microbial cell banking, GMP manufacturing (100mg-10g/batch), analytical development, and CMC writing.

3Lentiviral Vector CDMO
CategoryCore CDMO Module
Description

End-to-end lentiviral vector CDMO service for CAR-T, TCR-T, CAR-NK, genetically modified MSC/HSC, and in vivo CAR-T applications, powered by the proprietary LV-SMART® suspension platform with adherent and suspension systems, ten viral vector GMP production suites, and analytics.

4mRNA and LNP CDMO
CategoryCore CDMO Module
Description

End-to-end CRO and CDMO service for mRNA therapeutics including in vitro transcription, LNP encapsulation, plasmid linearization, capping/tailing, multi-step purification, LNP formulation, and fill/finish for both research-grade and GMP production.

5Bacterial Vector CDMO
CategoryCore CDMO Module
Description

Integrated CMC service for live and live-attenuated bacterial vectors used in gene therapy, oncolytic bacterial therapy, and vaccines, covering strain construction, microbial banking, process development, GMP production, analytical development, fill & finish, and regulatory submission for Salmonella, E. coli, Listeria, and related strains.

6Exosome CDMO
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Salvectors (Shaoxing Salvectors Biotechnology Ltd.)
Strategic tierCore — Exclusive Cdmo Partnership For Yb1-X7 Dual-Filing ProgramTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Exclusive CDMO partner for Salvectors' YB1-X7 Injection, an oncolytic bacteria therapy (Salmonella-based YB1-v3.0 platform). Porton Advanced provided end-to-end CMC services including strain construction, process development, GMP production, quality studies, release testing, and regulatory submission support, achieving dual US FDA + China NMPA IND clearance in solid tumors.

portonadvanced.com
Strategic tierFlagship — Strategic Gtm Alliance For Global Cell & Gene Therapy Sponsors Entering ChinaTypeStrategic or Co-development PartnerAnnounced on2026-04-26
Description

Signed a Memorandum of Understanding on April 26, 2026, to accelerate the development and clinical translation of cell and gene therapies globally, with particular emphasis on enabling Investigator-Initiated Trials (IITs) in China. Combines DHCG's regulatory, CMC, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics consulting with Porton Advanced's end-to-end GMP manufacturing infrastructure (lentiviral vectors, AAV, mRNA/LNP, plasmids, engineered cell therapies including CAR-T, CAR-NK, and iPSC-derived products). Porton Advanced brings 24 IND clearances across NMPA and FDA and experience supporting over 30 IITs to date.

Strategic tierMinor — Affiliated Consulting Practices Within The Dhcg Group That May Co-Engage On Porton Advanced Client ProgramsTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-26
Description

Dark Horse Consulting Group comprises three core business units (DHC, BioTechLogic, Converge Consulting), with Bruder Consulting & Venture Group (regenerative medicine) and CJP joining as Dark Horse Consulting companies in early 2026. These units extend DHCG's subject-matter expertise across strategy, operations, quality, regulatory, manufacturing, supply chain, commercial launch, and business optimization for biopharma clients engaged with Porton Advanced's CDMO services.

4T&L biotechnology (T&L Biotechnology Ltd.)
Strategic tierFlagship — Integrated Cgt Supply Chain PartnershipTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Strategic partnership announced March 12, 2026 to create a fully integrated CGT supply chain solution from critical raw materials to commercial manufacturing. T&L brings upstream GMP-grade raw materials (cell separation & activation magnetic beads, recombinant proteins, serum-free medium, cell culture kits), while Porton Advanced contributes downstream process development and large-scale manufacturing. Joint process optimization and quality control help clients overcome technical hurdles and shorten timelines.

portonadvanced.com
Strategic tierCore — Strategic Enterprise Partnership For In Vivo Car-TTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

CDMO services for CSPC's SYS6055 Injection, the first in vivo CAR-T therapy approved for clinical trials in China, indicated for relapsed/refractory aggressive B-cell lymphoma. Porton Advanced provided plasmid, lentiviral vector, and full CMC support.

6Gene MiNK Biotechnology (Beijing Gene MiNK Biotechnology Co., Ltd.)
Strategic tierCore — Exclusive Cdmo Partnership For Nk And Car-Nk PipelineTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Exclusive CDMO partner for Gene MiNK's NK cell therapy pipeline: QM101 Cell Injection (feeder-free, serum-free autologous NK for solid tumors) and QM103 Cell Injection (BCMA-targeted CAR-NK for RRMM). Both secured NMPA IND clearance. End-to-end support from plasmids to lentiviral vectors to CAR-NK manufacturing delivered in 10 months.

portonadvanced.com
Strategic tierImportant — Ophthalmic Cell Therapy Co-DevelopmentTypeStrategic or Co-development PartnerAnnounced on2025-05-15
Description

Collaboration announced May 15, 2025 to accelerate development of iPSC-derived retinal pigment epithelium cell (RPEC) transplantation therapy for blinding eye diseases such as age-related macular degeneration (AMD). Porton Advanced provides end-to-end CDMO services including iPSC reprogramming and cell banking, process optimization for RPE-directed differentiation, GMP manufacturing, rigorous quality studies, and IND application support. TongEYE contributes a proprietary induction method that shortens RPE differentiation from 120–150 days to ~25 days.

Strategic tierCore — First-In-China Clinical-Grade Flow Electroporation CapabilityTypeTechnology or IntegrationAnnounced on2024-06-25
Description

Porton Advanced introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument into its cell engineering platform, becoming the first cell engineering CDMO in China with this clinical-grade flow electroporation system. Supports flexible transfection volumes from research through cGMP production. Porton Advanced collaborates with MaxCyte's technical and compliance teams on process development and clinical production for multiple cell engineering projects at IIT, IND, and clinical-trial stages.

Strategic tierCore — Ai-Guided Aav Library Co-DevelopmentTypeStrategic or Co-development PartnerAnnounced on2023-11-08
Description

Strategic partnership announced November 8, 2023 to co-develop AI-driven AAV design solutions. BioMap contributes a 100B-parameter multimodal foundation model trained on 20M AAV viability data points and 3B protein data, covering 10+ serotypes with tissue-specific libraries. Porton Advanced contributes AAV capsid library plasmid construction, virus packaging, gene synthesis, and screening (in vivo NHP/mouse, in vitro 3D culture/organoid) to identify and validate candidate variants.

10DanausGT
Strategic tierMinor — Gene And Cell Engineering CollaborationTypeStrategic or Co-development PartnerAnnounced on2023-03-02
Description

Collaboration announced March 2, 2023 to accelerate the development of gene and cell engineering programs by combining DanausGT's pipeline with Porton Advanced's CDMO platform.

portonadvanced.com
Strategic tierMinor — Cgt Raw Materials AllianceTypeStrategic or Co-development PartnerAnnounced on2023-02-25
Description

Partnership announced February 25, 2023 to enhance Porton Advanced's CDMO technology platform through Yinjia Biosciences' CGT raw materials and process solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Cobra Biologics (Charles River)
TypeDirect peer
Description

Specialized viral vector and plasmid CDMO, now part of Charles River. Directly comparable to Porton Advanced's plasmid and LV/AAV CDMO modules for gene therapy developers.

TypeDirect peer
Description

The largest Chinese ATMP CDMO, providing plasmid, viral vector, and cell therapy manufacturing globally. Most directly comparable to Porton Advanced given the China-based GMP footprint and overlapping plasmid/LV/AAV/cell therapy offerings.

TypeDirect peer
Description

CDMO division of GenScript offering plasmid, viral vector, and cell therapy CMC services. Comparable in modality breadth (plasmid → LV → cell therapy) and in serving both Chinese and global CGT sponsors.

TypeDirect peer
Description

Global CDMO with cell and gene therapy capabilities, including viral vector and cell therapy manufacturing. Comparable as a multi-modality CGT CDMO serving similar biotech and pharma customers across geographies.

TypeBroad incumbent
Description

Large global CDMO with viral vector, cell therapy, and plasmid CDMO services, recently acquired by Novo Holdings. Competes with Porton Advanced for large commercial-stage CGT manufacturing programs and brings deeper commercial-scale experience.

TypeBroad incumbent
Description

One of the largest global CDMOs with significant cell and gene therapy capacity via its Cell & Gene Technologies platform. Competes at the upper end of commercial-stage CGT manufacturing where Porton Advanced is still building share.

TypeBroad incumbent
Description

Global CRO/CDMO with cell and gene therapy manufacturing, including viral vector CDMO. Overlaps with Porton Advanced's LV/AAV offering as part of a broader life-sciences services portfolio.

TypeEmerging player
Description

Emerging cell therapy CDMO focused on automated, high-throughput cell therapy manufacturing. Competes with Porton Advanced on cell engineering CMC services, particularly autologous CAR-T and CAR-NK programs.

TypeEmerging player
Description

Manufacturing technology company offering end-to-end biologics and cell/gene therapy services including viral vectors. Comparable to Porton Advanced's integrated CDMO approach and modality breadth.

TypeOthers
Description

Provider of clinical-grade flow electroporation technology, used by Porton Advanced in its cell engineering platform. A technology partner rather than direct competitor, but it represents a key infrastructure dependency and signals the broader CGT CDMO ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Porton Advanced Solutions

Cell and Gene Therapy CDMOportonadvanced.com

Porton Advanced Solutions is a privately held cell and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes to global pharmaceutical and biotech sponsors.

What Porton Advanced Solutions does

Porton Advanced Solutions is a privately held cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) founded in 2018 as a wholly-owned subsidiary of Porton Pharma Solutions, Ltd. (Shenzhen Stock Exchange: 300363). It is operationally headquartered in Cranbury, New Jersey (United States), with two cGMP manufacturing sites in Suzhou, China (Ascendas Park Campus and Mulberry Field Island / BioBay Campus). The company serves global pharmaceutical and biotechnology developers of advanced therapy medicinal products (ATMPs), serving 250+ customers across multiple modalities including cell therapies, gene therapies, mRNA therapeutics, oncolytic bacteria, and exosomes.

The company's core offering is an end-to-end ATMP platform spanning plasmids, viral vectors (lentivirus, AAV, oncolytic viruses, adenovirus), cell engineering (CAR-T, TCR-T, CAR-NK, TIL, MSC, HSC, iPSC-derived products), mRNA/LNP, bacterial vectors, and exosomes. Notable proprietary technology components include the LV-SMART® serum-free HEK293T suspension lentiviral platform (>5E07 TU/mL infectious titer, FDA DMF-registered MCB/WCB), the AAVantage® AI-guided AAV capsid library platform (co-developed with BioMap using a 100B-parameter multimodal LLM), an in vivo CAR-T LV capability at 1×10⁹ TU/mL with batch scales up to 1×10¹² TU, and clinical-grade MaxCyte ExPERT GTx flow electroporation (the first at a cell engineering CDMO in China). The firm supports iPSC-derived therapies at >1,000 batches/year scale and runs 215,000 sq ft of GMP space with 10 viral vector lines and 12 cell therapy suites (2 commercial). Quality systems are compliant with FDA, EU, and NMPA GMP requirements; 25 IND clearances have been supported with a stated 100% zero-deficiency submission success rate.

The business model combines several revenue streams: (1) fee-for-service CDMO contracts (quote-based, project-scoped) covering process development, GMP manufacturing, fill/finish, and analytical release for clinical and commercial programs; (2) sale of off-the-shelf FDA DMF-registered LV-SMART helper plasmids (VSV-G DMF #29485, Rev #29473, GagPol DMF #29421); (3) catalog research products (AAV packaging across 20+ serotypes at $1,399–$15,699 per unit, plasmid preparation, lentivirus, mRNA) with publicly listed pricing aimed at academic and industrial research customers; (4) pipeline licensing of internal and client CAR-T candidates (PAS-001 through PAS-011) to international innovators; and (5) managed Investigator-Initiated Trial (IIT) services bundling GMP manufacturing with regulatory, ethics/HGRAC submissions, PI selection, patient recruitment, and clinical data collection — most recently anchored by an MOU with Dark Horse Consulting Group (April 2026) targeting overseas sponsors entering China. Go-to-market is sales-led B2B with field account coverage, conference-driven demand generation (ASGCT 2024 Baltimore, 2026 Boston booth #831), gated scientific content (whitepapers, brochures, peer-reviewed publications), and channel partnerships with consulting firms (DHCG) and raw-material suppliers (T&L Biotechnology).

Porton Advanced Solutions firmographics

Firmographics
Name
Porton Advanced Solutions
Legal name
Porton Advanced Solutions LLC
Website
https://portonadvanced.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Porton Advanced Solutions is a privately held cell and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes to global pharmaceutical and biotech sponsors.
Ownership category
akta.pro rank

Porton Advanced Solutions industry classification

Industry
Product category
Cell and Gene Therapy CDMO
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy CDMO
  • Gene therapy CDMO
  • Plasmid manufacturing
  • Viral vector production
  • MRNA LNP services

Where Porton Advanced Solutions is headquartered

Location

Headquarters

HQ city
Cranbury
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Porton Advanced Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: Fee-for-service contract development and GMP manufacturing for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes, from process development through IND-enabling CMC, GMP production, fill/finish, and release testing. Quote-based, project-scoped engagements with milestone billing.
  2. Pipeline Licensing Service: Licensing-out of client/internal cell therapy pipelines (e.g., PAS-001 NKG2DL CAR-T for glioblastoma/colorectal/HCC, PAS-009/PAS-010 Mesothelin CAR-T, PAS-011 CD19 CAR-T for R/R B-ALL which is NMPA-approved) to international innovators. Generates licensing/royalty revenue.
  3. Off-the-Shelf Helper Plasmid Products: Sale of ready-to-use, FDA DMF-registered LV-SMART™ helper plasmids (VSV-G DMF #29485, Rev DMF #29473, GagPol DMF #29421) in 1mg, 5mg, and 10mg vials for lentiviral vector manufacturing.
  4. Research & Preclinical Catalog Products: Catalogue sales of AAV packaging (20+ serotypes, $1,399–$15,699 per unit), plasmid DNA preparation (miniprep through industrial grade), lentivirus, and mRNA products to academic and industrial research customers with publicly listed unit pricing.
  5. Investigator-Initiated Trial (IIT) End-to-End Services: Managed IIT service bundles covering GMP manufacturing, IIT application, ethics/HGRAC submissions, PI and site selection, patient recruitment, clinical data collection, and analysis — coordinated with clinical/nonclinical CRO partners as project-managed services.

Pricing tiers

ModelBillingPrice
Unit Pricing—AAV packaging off-the-shelf (research-grade)
Unit Pricing—Plasmid preparation services (research-grade)
Unit Pricing—LV-SMART™ GMP-grade off-the-shelf helper plasmids
Other—CDMO clinical & commercial manufacturing

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Porton Advanced Solutions product offering

Product offering

Core offering

Porton Advanced Solutions provides end-to-end contract development and manufacturing (CDMO) services for advanced therapy medicinal products (ATMPs), spanning plasmid DNA, lentiviral and AAV viral vectors, mRNA/LNP, bacterial vectors, exosomes, and engineered cell therapies (CAR-T, TCR-T, CAR-NK, TIL, MSC, iPSC-derived). The company operates from US headquarters in Cranbury, NJ and two cGMP manufacturing sites in Suzhou, China, offering process development, analytical/QC testing, GMP manufacturing, fill/finish, regulatory support (NMPA/FDA/EMA), and pipeline licensing for cell and gene therapy developers worldwide.

Product overview

Porton Advanced Solutions delivers an integrated platform-plus-modules ATMP CRO/CDMO architecture organized around three end-to-end service pillars: Research & Preclinical Services (vector construction, virus packaging, mRNA and LNP, gene editing, off-the-shelf products), CDMO Solutions (Cell Engineering CMC Services, Plasmid, Lentivirus, mRNA and LNP, Bacterial Vector, Exosome, iPSC-derived Cell Therapies, GMP Lentivirus Helper Plasmids, LV-SMART®-LVVs Suspension Production Platform, Adeno-Associated Virus), and Innovative Services (Integrated CMC Service for Investigator-Initiated Clinical Trials, Pipeline Licensing Service, Analytical Development and Testing). The LV-SMART®-LVVs Suspension Production Platform and AAVantage® Novel AAV Capsid Library Platform function as cross-cutting proprietary platforms that power the Lentivirus and AAV CDMO modules respectively. GMP Manufacturing (160,000 m² across two Suzhou sites) and the seven Functional Analytical Platforms (Physicochemical & Characterization, Microbiology, Molecular Studies, Biochemical, Cell Function, FACS) underpin all modules with shared QC, Process Development, and Quality Systems infrastructure. The offering is a single integrated CDMO platform with named product modules rather than a unified packaged product, supported by Pipeline Licensing of CAR-T candidates (PAS-001 to PAS-011) for in-licensing partners.

Differentiator

Problem solved

Functional benefit

Brands

  • LV-SMART®: Proprietary HEK293T-based lentiviral vector suspension, serum-free GMP manufacturing platform developed by Porton Advanced, with FDA DMF-registered master cell bank.
  • AAVantage®

Products and services

  • Cell Engineering CMC Services End-to-end CMC services for engineered cell therapies including CAR-T, TCR-T, CAR-NK, MSC, TIL, NK, and iPSC-derived cell products, with full process development, cGMP manufacturing, testing, and regulatory assistance for global cell therapy developers.
  • Plasmid CDMO Plasmid DNA manufacturing service for naked plasmid DNA, mRNA, AAV, lentiviral, and episomal iPSC reprogramming vectors, including microbial cell banking, GMP manufacturing (100mg-10g/batch), analytical development, and CMC writing.
  • Lentiviral Vector CDMO End-to-end lentiviral vector CDMO service for CAR-T, TCR-T, CAR-NK, genetically modified MSC/HSC, and in vivo CAR-T applications, powered by the proprietary LV-SMART® suspension platform with adherent and suspension systems, ten viral vector GMP production suites, and analytics.
  • mRNA and LNP CDMO End-to-end CRO and CDMO service for mRNA therapeutics including in vitro transcription, LNP encapsulation, plasmid linearization, capping/tailing, multi-step purification, LNP formulation, and fill/finish for both research-grade and GMP production.
  • Bacterial Vector CDMO Integrated CMC service for live and live-attenuated bacterial vectors used in gene therapy, oncolytic bacterial therapy, and vaccines, covering strain construction, microbial banking, process development, GMP production, analytical development, fill & finish, and regulatory submission for Salmonella, E. coli, Listeria, and related strains.
  • Exosome CDMO

Quantifiable outcome

  • 100% submission success rate (zero-deficiency IND filings)
  • +6 more outcomes

Companies that use Porton Advanced Solutions

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Porton Advanced Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature8 records

Porton Advanced Solutions partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core — exclusive cdmo partnership for yb1-x7 dual-filing program, flagship — strategic gtm alliance for global cell & gene therapy sponsors entering china, minor — affiliated consulting practices within the dhcg group that may co-engage on porton advanced client programs, flagship — integrated cgt supply chain partnership, core — strategic enterprise partnership for in vivo car-t, core — exclusive cdmo partnership for nk and car-nk pipeline, important — ophthalmic cell therapy co-development, core — first-in-china clinical-grade flow electroporation capability, core — ai-guided aav library co-development, minor — gene and cell engineering collaboration and minor — cgt raw materials alliance.

  • Salvectors (Shaoxing Salvectors Biotechnology Ltd.)core — exclusive cdmo partnership for yb1-x7 dual-filing programStrategic or Co-development Partner · 20 May 2026Exclusive CDMO partner for Salvectors' YB1-X7 Injection, an oncolytic bacteria therapy (Salmonella-based YB1-v3.0 platform). Porton Advanced provided end-to-end CMC services including strain construction, process development, GMP production, quality studies, release testing, and regulatory submission support, achieving dual US FDA + China NMPA IND clearance in solid tumors.
  • Dark Horse Consulting Group (DHCG)flagship — strategic gtm alliance for global cell & gene therapy sponsors entering chinaStrategic or Co-development Partner · 26 April 2026Signed a Memorandum of Understanding on April 26, 2026, to accelerate the development and clinical translation of cell and gene therapies globally, with particular emphasis on enabling Investigator-Initiated Trials (IITs) in China. Combines DHCG's regulatory, CMC, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics consulting with Porton Advanced's end-to-end GMP manufacturing infrastructure (lentiviral vectors, AAV, mRNA/LNP, plasmids, engineered cell therapies including CAR-T, CAR-NK, and iPSC-derived products). Porton Advanced brings 24 IND clearances across NMPA and FDA and experience supporting over 30 IITs to date.
  • DHCG business units (DHC, BioTechLogic, Converge Consulting, Bruder Consulting & Venture Group, CJP)minor — affiliated consulting practices within the dhcg group that may co-engage on porton advanced client programsImplementation/ SI/ Consulting Partner · 26 April 2026Dark Horse Consulting Group comprises three core business units (DHC, BioTechLogic, Converge Consulting), with Bruder Consulting & Venture Group (regenerative medicine) and CJP joining as Dark Horse Consulting companies in early 2026. These units extend DHCG's subject-matter expertise across strategy, operations, quality, regulatory, manufacturing, supply chain, commercial launch, and business optimization for biopharma clients engaged with Porton Advanced's CDMO services.
  • T&L biotechnology (T&L Biotechnology Ltd.)flagship — integrated cgt supply chain partnershipStrategic or Co-development Partner · 12 March 2026Strategic partnership announced March 12, 2026 to create a fully integrated CGT supply chain solution from critical raw materials to commercial manufacturing. T&L brings upstream GMP-grade raw materials (cell separation & activation magnetic beads, recombinant proteins, serum-free medium, cell culture kits), while Porton Advanced contributes downstream process development and large-scale manufacturing. Joint process optimization and quality control help clients overcome technical hurdles and shorten timelines.
  • CSPC Pharmaceutical Group Limitedcore — strategic enterprise partnership for in vivo car-tStrategic or Co-development Partner · 29 January 2026CDMO services for CSPC's SYS6055 Injection, the first in vivo CAR-T therapy approved for clinical trials in China, indicated for relapsed/refractory aggressive B-cell lymphoma. Porton Advanced provided plasmid, lentiviral vector, and full CMC support.
  • Gene MiNK Biotechnology (Beijing Gene MiNK Biotechnology Co., Ltd.)core — exclusive cdmo partnership for nk and car-nk pipelineStrategic or Co-development Partner · 11 December 2025Exclusive CDMO partner for Gene MiNK's NK cell therapy pipeline: QM101 Cell Injection (feeder-free, serum-free autologous NK for solid tumors) and QM103 Cell Injection (BCMA-targeted CAR-NK for RRMM). Both secured NMPA IND clearance. End-to-end support from plasmids to lentiviral vectors to CAR-NK manufacturing delivered in 10 months.
  • TongEye Medical Technology (TongEYE)important — ophthalmic cell therapy co-developmentStrategic or Co-development Partner · 15 May 2025Collaboration announced May 15, 2025 to accelerate development of iPSC-derived retinal pigment epithelium cell (RPEC) transplantation therapy for blinding eye diseases such as age-related macular degeneration (AMD). Porton Advanced provides end-to-end CDMO services including iPSC reprogramming and cell banking, process optimization for RPE-directed differentiation, GMP manufacturing, rigorous quality studies, and IND application support. TongEYE contributes a proprietary induction method that shortens RPE differentiation from 120–150 days to ~25 days.
  • MaxCytecore — first-in-china clinical-grade flow electroporation capabilityTechnology or Integration · 25 June 2024Porton Advanced introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument into its cell engineering platform, becoming the first cell engineering CDMO in China with this clinical-grade flow electroporation system. Supports flexible transfection volumes from research through cGMP production. Porton Advanced collaborates with MaxCyte's technical and compliance teams on process development and clinical production for multiple cell engineering projects at IIT, IND, and clinical-trial stages.
  • BioMapcore — ai-guided aav library co-developmentStrategic or Co-development Partner · 8 November 2023Strategic partnership announced November 8, 2023 to co-develop AI-driven AAV design solutions. BioMap contributes a 100B-parameter multimodal foundation model trained on 20M AAV viability data points and 3B protein data, covering 10+ serotypes with tissue-specific libraries. Porton Advanced contributes AAV capsid library plasmid construction, virus packaging, gene synthesis, and screening (in vivo NHP/mouse, in vitro 3D culture/organoid) to identify and validate candidate variants.
  • DanausGTminor — gene and cell engineering collaborationStrategic or Co-development Partner · 2 March 2023Collaboration announced March 2, 2023 to accelerate the development of gene and cell engineering programs by combining DanausGT's pipeline with Porton Advanced's CDMO platform.
  • Yinjia Biosciencesminor — cgt raw materials allianceStrategic or Co-development Partner · 25 February 2023Partnership announced February 25, 2023 to enhance Porton Advanced's CDMO technology platform through Yinjia Biosciences' CGT raw materials and process solutions.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Porton Advanced Solutions competitors and assessment

Company assessment

Direct peers

  • Cobra Biologics (Charles River): Specialized viral vector and plasmid CDMO, now part of Charles River. Directly comparable to Porton Advanced's plasmid and LV/AAV CDMO modules for gene therapy developers.
  • WuXi Advanced Therapies (WuXi AppTec ATU): The largest Chinese ATMP CDMO, providing plasmid, viral vector, and cell therapy manufacturing globally. Most directly comparable to Porton Advanced given the China-based GMP footprint and overlapping plasmid/LV/AAV/cell therapy offerings.
  • GenScript ProBio: CDMO division of GenScript offering plasmid, viral vector, and cell therapy CMC services. Comparable in modality breadth (plasmid → LV → cell therapy) and in serving both Chinese and global CGT sponsors.
  • AGC Biologics: Global CDMO with cell and gene therapy capabilities, including viral vector and cell therapy manufacturing. Comparable as a multi-modality CGT CDMO serving similar biotech and pharma customers across geographies.

Broad incumbents

  • Catalent (Novo Holdings): Large global CDMO with viral vector, cell therapy, and plasmid CDMO services, recently acquired by Novo Holdings. Competes with Porton Advanced for large commercial-stage CGT manufacturing programs and brings deeper commercial-scale experience.
  • Lonza: One of the largest global CDMOs with significant cell and gene therapy capacity via its Cell & Gene Technologies platform. Competes at the upper end of commercial-stage CGT manufacturing where Porton Advanced is still building share.
  • Charles River Laboratories: Global CRO/CDMO with cell and gene therapy manufacturing, including viral vector CDMO. Overlaps with Porton Advanced's LV/AAV offering as part of a broader life-sciences services portfolio.

Emerging players

  • Cellares: Emerging cell therapy CDMO focused on automated, high-throughput cell therapy manufacturing. Competes with Porton Advanced on cell engineering CMC services, particularly autologous CAR-T and CAR-NK programs.
  • Resilience: Manufacturing technology company offering end-to-end biologics and cell/gene therapy services including viral vectors. Comparable to Porton Advanced's integrated CDMO approach and modality breadth.

Others

  • MaxCyte: Provider of clinical-grade flow electroporation technology, used by Porton Advanced in its cell engineering platform. A technology partner rather than direct competitor, but it represents a key infrastructure dependency and signals the broader CGT CDMO ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Porton Advanced Solutions social profiles

Digital presence

Porton Advanced Solutions compliance and trust

Trust signal

Compliance7 records

Porton Advanced Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Porton Advanced Solutions leadership team

Management profile

Number of profiles

Profiles3 records

Porton Advanced Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Porton Advanced Solutions funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Porton Advanced Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Porton Advanced Solutions

What does Porton Advanced Solutions do?

Porton Advanced Solutions provides end-to-end contract development and manufacturing (CDMO) services for advanced therapy medicinal products (ATMPs), spanning plasmid DNA, lentiviral and AAV viral vectors, mRNA/LNP, bacterial vectors, exosomes, and engineered cell therapies (CAR-T, TCR-T, CAR-NK, TIL, MSC, iPSC-derived). The company operates from US headquarters in Cranbury, NJ and two cGMP manufacturing sites in Suzhou, China, offering process development, analytical/QC testing, GMP manufacturing, fill/finish, regulatory support (NMPA/FDA/EMA), and pipeline licensing for cell and gene therapy developers worldwide.

Is Porton Advanced Solutions a public or private company?

Porton Advanced Solutions is a private company. It is classified as corporate owned and is currently operating.

When was Porton Advanced Solutions founded?

Porton Advanced Solutions was founded in 2018. It employs 11 to 50 people.

Where is Porton Advanced Solutions based?

Porton Advanced Solutions is headquartered in Cranbury, United States, in the North America region.

How does Porton Advanced Solutions make money?

Five revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are pipeline Licensing Service, off-the-Shelf Helper Plasmid Products, research & Preclinical Catalog Products and investigator-Initiated Trial (IIT) End-to-End Services.

Who are Porton Advanced Solutions's main competitors?

Direct peers on record are Cobra Biologics (Charles River), WuXi Advanced Therapies (WuXi AppTec ATU), GenScript ProBio and AGC Biologics. Broad incumbents are Catalent (Novo Holdings), Lonza and Charles River Laboratories. Emerging players are Cellares and Resilience. MaxCyte is listed as an others.

Does Porton Advanced Solutions have an API?

No public API is recorded for Porton Advanced Solutions.

What industry is Porton Advanced Solutions in?

Porton Advanced Solutions's product category is Cell and Gene Therapy CDMO. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePorton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to CommercializationPorton Advanced Solutions Ltd. has been granted a Drug Manufacturing License (Class C) by China's National Medical Products Administration (NMPA), enabling the company to undertake commercial contract manufacturing for Cell and Gene Therapy products. This license extends their CDMO services from process development and clinical production through to full commercialization, following successful regulatory inspection of their GMP-compliant facilities in China. The milestone positions Porton Advanced, which has served over 200 global clients with a 100% IND submission success rate, to offer end-to-end manufacturing services as a CDMO partner.PR Newswire APACPorton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to CommercializationPorton Advanced Solutions received a Class C Drug Manufacturing License from China's NMPA, enabling commercial contract manufacturing of cell and gene therapy products. The license validates its GMP-compliant facilities and end-to-end CDMO services, supporting over 200 clients and 26 global IND approvals. The company will align with client launch schedules to prepare for commercial supply.PR NewswirePorton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to CommercializationPorton Advanced Solutions received a Class C Drug Manufacturing License from China's NMPA, enabling commercial contract manufacturing of cell and gene therapy products. The license validates its GMP-compliant facilities and end-to-end CDMO services, supporting over 200 clients and 26 global IND approvals. The company will align with client launch schedules to prepare for commercial supply.PR NewswirePorton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) AcceptancePorton Advanced announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has been accepted for filing by the FDA's Center for Biologics Evaluation and Research under Drug Master File (DMF) #32973. This regulatory milestone enables sponsors advancing exosome programs to reference DMF #32973 in their own regulatory submissions, accelerating U.S. FDA review pathways and reducing duplicative documentation. Porton Advanced, a subsidiary of Porton Pharma Solutions headquartered in Cranbury, New Jersey with GMP facilities in Suzhou, China, provides end-to-end CDMO solutions for advanced therapy medicinal products including exosomes.PR NewswirePorton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient MarketPorton Advanced announced that its proprietary stem cell-derived exosomes have been officially listed under the International Nomenclature of Cosmetic Ingredients (INCI), a globally recognized naming standard adopted by over 70 countries. This INCI listing confirms the product meets international safety, compliance, and quality control standards, removing regulatory and traceability barriers for cosmetic brands worldwide. The milestone marks a key step in the company's strategic expansion of its CDMO services into exosome raw materials and cosmetic applications.GlobeNewswireDark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in ChinaDark Horse Consulting Group and Porton Advanced signed an MOU to collaborate on cell and gene therapies, focusing on Investigator-Initiated Trials in China. Porton Advanced holds 24 IND clearances across NMPA and FDA and has supported over 30 IITs. The partnership aims to streamline manufacturing and regulatory pathways for clients.Straits ResearchChina Cell and Gene Therapy Manufacturing QC Market Growth Analysis 2033The China cell and gene therapy manufacturing QC market was valued at USD 304.33 million in 2024 and is projected to reach USD 2,615.64 million by 2033, growing at a CAGR of 27.0%. Key drivers include China's favorable regulatory environment, government investment in biotech infrastructure, and over 1,000 active clinical trials as of 2023, while high costs and complexity of QC procedures pose challenges. Notable partnerships include Gilead Sciences co-developing cell therapies with Fosun Kite in 2022, and Chinese startups Porton Advanced Solutions and Yinjia forming a strategic alliance for CGT raw materials in February 2023.The Manila TimesPorton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy DevelopmentPorton Advanced announced a partnership with Eureka Therapeutics to accelerate T-cell therapy development, leveraging its GMP manufacturing capabilities. The collaboration aims to support Eureka's clinical trials, with Porton providing CAR-T manufacturing services for Investigator-Initiated Trials. Porton has supported over 60 ATMP projects with a flawless release success rate.PR NewswirePorton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative TherapeuticsPorton Advanced Solutions and Geneseed Biotech announced a strategic collaboration on July 29, 2024, to advance circRNA innovative therapeutics. The partnership combines Porton's end-to-end cell and gene therapy CDMO services with Geneseed's patented circRNA drug development technologies to accelerate clinical translation and industrialization.